| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: =99.13%
| Targets |
Methoxy-PMS targets the electron transport chain between NAD(P)H and tetrazolium dyes. It acts as an electron mediator, receiving electrons from NADH or NADPH at the membrane or inside the cell and transferring them to WST-8 or other tetrazolium salts in the extracellular environment. By facilitating this electron transfer, Methoxy-PMS enables the reduction of tetrazolium dyes to colored formazan products, which can be quantified spectrophotometrically. The compound does not have a specific therapeutic target but is a critical reagent for cell viability and proliferation assays.
|
|---|---|
| ln Vitro |
It is not cytotoxic to use methyl-PMS in cell culture media. Methoxy-PMS delivers electrons to WST-8, which surrounds the cell's outer membrane, after receiving them from NADH or NADPH at the cell membrane or inside the cell [2].
Methoxy-PMS has no direct biological activity as a therapeutic agent. Its primary function is as an electron mediator in cell viability assays, particularly in combination with WST-8. The compound receives electrons from NADH or NADPH and passes them to WST-8, resulting in the formation of a water-soluble formazan dye. The amount of formazan produced is directly proportional to the number of viable cells, making Methoxy-PMS an essential component of the widely used CCK-8 cell proliferation and cytotoxicity assay. The compound has no cytotoxicity in cell culture media, making it suitable for long-term cell culture applications. |
| ln Vivo |
The WST8/1-methoxy PMS assay was found to have 72% sensitivity and 98% specificity when compared to the commercial enzymatic assay and the AUC was 0.904, suggesting good agreement. Misclassifications were at borderline values of G6PD activity between mild and normal levels, or related to outlier haemoglobin values (<8.0 gHb/dl or >14 gHb/dl) associated with ongoing anaemia or recent haemolytic crises. Although severe G6PD deficiency was not found in the area, the test enabled identification of low G6PD activity. The assay was found to be highly robust for field use; showing less light sensitivity, good performance over a wide temperature range, and good capacity for medium-to-long term storage [2].
Methoxy-PMS is not evaluated for in vivo activity in animal models as it is a laboratory reagent rather than a therapeutic agent. Its application is in cell-based assays for measuring cell viability, proliferation, and cytotoxicity in vitro. The compound is not administered to animals for therapeutic purposes. |
| Enzyme Assay |
The WST8/1-methoxy PMS method, recently adapted for field use, was validated using a gold standard enzymatic assay (R&D Diagnostics Ltd ®) in a study involving 235 children under five years of age, who were recruited by random selection from a cohort study in Tororo, Uganda. Blood spots were collected by finger-prick onto filter paper at routine visits, and G6PD activity was determined by both tests. Performance of the WST8/1-methoxy PMS test under various temperature, light, and storage conditions was evaluated [2].
In vitro non-cell assays using Methoxy-PMS typically involve the reduction of tetrazolium dyes in the presence of NADH or NADPH. The compound is incubated with NADH or NADPH and a tetrazolium dye (such as WST-8), and the formation of the reduced formazan product is measured spectrophotometrically at 450 nm or other appropriate wavelengths. These assays are used to validate the performance of Methoxy-PMS as an electron mediator and to quantify the reducing capacity of samples. |
| Cell Assay |
In vitro cell-based assays using Methoxy-PMS are performed in cell viability and cytotoxicity assays such as the CCK-8 assay. Cells are cultured in 96-well plates and treated with test compounds. Methoxy-PMS and WST-8 are added to the culture medium, and the plate is incubated at 37°C for 1-4 hours. The amount of formazan produced is measured spectrophotometrically at 450 nm, and the absorbance is directly proportional to the number of viable cells. The compound has no cytotoxicity, allowing for accurate assessment of cell viability.
|
| Animal Protocol |
In vivo animal studies are not performed with Methoxy-PMS as it is a laboratory reagent rather than a therapeutic agent. The compound is not intended for in vivo administration. Its use is limited to in vitro cell-based assays for research purposes.
|
| ADME/Pharmacokinetics |
Methoxy-PMS has a molecular weight of 336.36 g/mol and a molecular formula of C₁₅H₁₆N₂O₅S. It is also known as 1-Methoxy PMS and 1-methoxy-5-methylphenazinium methyl sulfate. The compound is a stable electron-transport mediator with no cytotoxicity. It is soluble in DMSO and should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic properties are not applicable as the compound is not used in vivo.
|
| Toxicity/Toxicokinetics |
Methoxy-PMS is considered to have low toxicity as a laboratory reagent. It has no cytotoxicity in cell culture media. Standard laboratory safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. The compound is classified as a research reagent and is not intended for human therapeutic use. Comprehensive toxicological studies have not been performed.
|
| References |
|
| Additional Infomation |
Methoxy-PMS is a stable electron-transport mediator between NAD(P)H and tetrazolium dyes. It is also known as 1-Methoxy PMS. The compound is an active oxygen formation inducer that receives electrons from NADH or NADPH and passes them to WST-8 for colorimetric detection. Methoxy-PMS has no cytotoxicity and is widely used in cell viability assays such as the CCK-8 assay. Not approved for therapeutic use; intended for research purposes only.
|
| Molecular Formula |
C₁₅H₁₆N₂O₅S
|
|---|---|
| Molecular Weight |
336.36
|
| Exact Mass |
336.078
|
| CAS # |
65162-13-2
|
| PubChem CID |
127832
|
| Appearance |
Brown to reddish brown solid
|
| Melting Point |
172 °C
|
| LogP |
2.394
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
362
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(=O)(=O)([O-])OC([H])([H])[H].O(C([H])([H])[H])C1=C([H])C([H])=C([H])C2C1=NC1=C([H])C([H])=C([H])C([H])=C1[N+]=2C([H])([H])[H]
|
| InChi Key |
MASUWVVNWALEEM-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C14H13N2O.CH4O4S/c1-16-11-7-4-3-6-10(11)15-14-12(16)8-5-9-13(14)17-2;1-5-6(2,3)4/h3-9H,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
|
| Chemical Name |
1-methoxy-5-methylphenazin-5-ium;methyl sulfate
|
| Synonyms |
1-Methoxy PMS 1-Methoxyphenazine methosulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~30 mg/mL (~89.19 mM)
H2O : ~6.67 mg/mL (~19.83 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 9.09 mg/mL (27.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9730 mL | 14.8650 mL | 29.7301 mL | |
| 5 mM | 0.5946 mL | 2.9730 mL | 5.9460 mL | |
| 10 mM | 0.2973 mL | 1.4865 mL | 2.9730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA